• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球范围内采用 H. pylori 检测-治疗根除疗法的趋势与胃癌预防策略

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

机构信息

Fellowship Training Center, Medical Education Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.

出版信息

J Gastroenterol. 2018 Mar;53(3):354-361. doi: 10.1007/s00535-017-1407-1. Epub 2017 Nov 14.

DOI:10.1007/s00535-017-1407-1
PMID:29138921
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5847180/
Abstract

Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

摘要

幽门螺杆菌相关性胃炎可导致胃癌的发生。京都全球共识报告推荐对幽门螺杆菌胃炎进行根除治疗以预防胃癌。为了管理幽门螺杆菌感染,考虑到克拉霉素和甲硝唑耐药的地区差异,选择合适的方案很重要。含喹诺酮类和利福布汀的方案可作为三线和四线挽救治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/a4e39561fddc/535_2017_1407_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/15b426135d54/535_2017_1407_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/23318b8d62ee/535_2017_1407_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/a4e39561fddc/535_2017_1407_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/15b426135d54/535_2017_1407_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/23318b8d62ee/535_2017_1407_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a1/5847180/a4e39561fddc/535_2017_1407_Fig3_HTML.jpg

相似文献

1
World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.全球范围内采用 H. pylori 检测-治疗根除疗法的趋势与胃癌预防策略
J Gastroenterol. 2018 Mar;53(3):354-361. doi: 10.1007/s00535-017-1407-1. Epub 2017 Nov 14.
2
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.在各种治疗策略中,联合治疗对幽门螺杆菌的根除率最高。
World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351.
3
[Helicobacter pylori-associated diseases].[幽门螺杆菌相关疾病]
Gastroenterol Hepatol. 2015 Sep;38 Suppl 1:39-48. doi: 10.1016/S0210-5705(15)30018-2.
4
Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients.评估伊朗胃癌和胃炎患者石蜡包埋胃活检标本中幽门螺杆菌 23S rRNA、rdxA 和 frxA 基因的突变。
J Gastrointest Cancer. 2021 Mar;52(1):207-211. doi: 10.1007/s12029-020-00386-z.
5
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.抗生素耐药性不断增加的时代下针对[具体病症,原文缺失]的新型有效治疗方案
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
6
Impact of health insurance coverage for gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data.日本胃炎医疗保险覆盖范围对根除治疗趋势的影响:基于真实世界数据的回顾性观察研究和模拟研究
BMJ Open. 2017 Jul 31;7(7):e015855. doi: 10.1136/bmjopen-2017-015855.
7
Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan.日本通过基因检测评估幽门螺杆菌对喹诺酮类和克拉霉素的耐药性。
J Gastroenterol Hepatol. 2011 Sep;26(9):1457-61. doi: 10.1111/j.1440-1746.2011.06815.x.
8
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.幽门螺杆菌:当前诊断与管理策略综述。
Dig Dis Sci. 2020 Jul;65(7):1917-1931. doi: 10.1007/s10620-020-06193-7.
9
Screening and eradication of for gastric cancer prevention: the Taipei global consensus.胃癌预防的筛查和根除:台北全球共识。
Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1.
10
[Expanded indication of National Health Insurance for H. pylori associated gastritis].[国家健康保险对幽门螺杆菌相关性胃炎的适应症扩大]
Nihon Rinsho. 2014 May;72(5):967-76.

引用本文的文献

1
Barnacle-like lesions in the gastric mucosa: Clinicopathological study of a novel endoscopic finding.胃黏膜中的藤壶样病变:一项新型内镜检查发现的临床病理研究
Endosc Int Open. 2025 Jul 29;13:a26457506. doi: 10.1055/a-2645-7506. eCollection 2025.
2
The Prevalence of Infection in the Adult Population of Russia: A Systematic Review and Meta-Analysis.俄罗斯成年人群感染率:系统评价与荟萃分析
Epidemiologia (Basel). 2025 Aug 12;6(3):47. doi: 10.3390/epidemiologia6030047.
3
Design of a multi-epitope vaccine candidate against Helicobacter pylori in gastric cancer: an immunoinformatic approach.

本文引用的文献

1
Different Pathophysiology of Gastritis between East and West? An Asian Perspective.东西方胃炎的病理生理学差异?亚洲视角。
Inflamm Intest Dis. 2016 Oct;1(3):123-128. doi: 10.1159/000446301. Epub 2016 May 20.
2
Acquisition of double mutation in caused high resistance to sitafloxacin in after unsuccessful eradication with sitafloxacin-containing regimens.在含西他沙星的治疗方案根除失败后,[具体对象]中双突变的获得导致对西他沙星产生高度耐药性。
United European Gastroenterol J. 2018 Apr;6(3):391-397. doi: 10.1177/2050640617737215. Epub 2017 Oct 8.
3
Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan.
一种针对胃癌中幽门螺杆菌的多表位疫苗候选物的设计:一种免疫信息学方法。
GMS Hyg Infect Control. 2025 Jun 16;20:Doc27. doi: 10.3205/dgkh000556. eCollection 2025.
4
Helicobacter pylori eradication and gastric cancer prevention in a pooled analysis of large-scale cohort studies in Japan.日本大规模队列研究的汇总分析中幽门螺杆菌根除与胃癌预防
Sci Rep. 2025 Jul 1;15(1):21307. doi: 10.1038/s41598-025-00713-z.
5
Endoscopic Diagnosis of Early Gastric Cancer and High-Risk Gastritis.早期胃癌及高危胃炎的内镜诊断
Korean J Helicobacter Up Gastrointest Res. 2024 Dec;24(4):311-318. doi: 10.7704/kjhugr.2024.0047. Epub 2024 Dec 4.
6
Birth cohort and age-specific trends in global seroprevalence: a scoping review.全球血清阳性率的出生队列和特定年龄趋势:一项范围综述。
Lancet Reg Health Am. 2024 Aug 29;41:100877. doi: 10.1016/j.lana.2024.100877. eCollection 2025 Jan.
7
Immune Cell Crisis and Excess Histopathological Features During the Development and Progression of Infection in the Gastric Mucosa.胃黏膜感染发生发展过程中的免疫细胞危机及过多组织病理学特征
Int J Gen Med. 2025 Mar 6;18:1345-1357. doi: 10.2147/IJGM.S474925. eCollection 2025.
8
Should Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.幽门螺杆菌标准三联疗法后二线治疗中是否应包含甲硝唑?:随机对照试验的系统评价和荟萃分析
Helicobacter. 2025 Jan-Feb;30(1):e70010. doi: 10.1111/hel.70010.
9
Immune cell changes in infection-induced glandular epithelial cell damage of the gastric mucosa.感染引起的胃黏膜腺上皮细胞损伤中的免疫细胞变化。
Ann Med. 2024 Dec;56(1):2425072. doi: 10.1080/07853890.2024.2425072. Epub 2024 Nov 8.
10
Initiation of a Screening Program: Enhancing Healthcare at Juntendo University.启动筛查项目:提升顺天堂大学的医疗服务水平。
Juntendo Iji Zasshi. 2024 May 24;70(3):214-220. doi: 10.14789/jmj.JMJ23-0043-OA. eCollection 2024.
日本对胃癌的幽门螺杆菌根除治疗的影响。
Helicobacter. 2017 Oct;22(5). doi: 10.1111/hel.12415. Epub 2017 Aug 3.
4
Effects of patient age and choice of antisecretory agent on success of eradication therapy for infection.患者年龄和抗分泌药物的选择对感染根除治疗成功率的影响。
J Clin Biochem Nutr. 2017 May;60(3):208-210. doi: 10.3164/jcbn.16-86. Epub 2017 Feb 16.
5
Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China.10 天铋剂四联疗法作为一线治疗方案用于治疗幽门螺杆菌相关慢性胃炎的有效性:中国的一项前瞻性随机研究。
Clin Microbiol Infect. 2017 Jun;23(6):391-395. doi: 10.1016/j.cmi.2016.12.032. Epub 2017 Jan 7.
6
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
7
Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India.印度北部地区幽门螺杆菌分离株的抗菌药敏谱分析。
J Glob Antimicrob Resist. 2016 Jun;5:51-6. doi: 10.1016/j.jgar.2015.09.009. Epub 2015 Nov 26.
8
Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.利福布汀为基础的 10 天和 14 天三联疗法作为幽门螺杆菌根除的三线和四线方案:一项初步研究。
United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13.
9
Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies.基于左氧氟沙星的三联疗法及高剂量质子泵抑制剂-阿莫西林双联根除疗法对一线和二线治疗失败后幽门螺杆菌的疗效
Int Sch Res Notices. 2014 Dec 16;2014:631501. doi: 10.1155/2014/631501. eCollection 2014.
10
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.沃克(富马酸沃克替唑胺),一种新型钾离子竞争性酸阻滞剂,作为一线和二线三联疗法的组成部分用于根除幽门螺杆菌:一项III期随机双盲研究。
Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2.